Review



anti-mouse integrin α5β1 monoclonal antibody  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Merck & Co anti-mouse integrin α5β1 monoclonal antibody
    Anti Mouse Integrin α5β1 Monoclonal Antibody, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-mouse integrin α5β1 monoclonal antibody/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    anti-mouse integrin α5β1 monoclonal antibody - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    94
    Bioss rabbit polyclonal α5β1 integrin antibody
    Rabbit Polyclonal α5β1 Integrin Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal α5β1 integrin antibody/product/Bioss
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal α5β1 integrin antibody - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    90
    Millipore blocking antibody recognizing α5β1 integrin millipore cat# mab2514
    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against <t>α5β1</t> <t>integrin</t> and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.
    Blocking Antibody Recognizing α5β1 Integrin Millipore Cat# Mab2514, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking antibody recognizing α5β1 integrin millipore cat# mab2514/product/Millipore
    Average 90 stars, based on 1 article reviews
    blocking antibody recognizing α5β1 integrin millipore cat# mab2514 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Millipore anti-integrin α5β1 primary antibody mab2514
    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against <t>α5β1</t> <t>integrin</t> and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.
    Anti Integrin α5β1 Primary Antibody Mab2514, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-integrin α5β1 primary antibody mab2514/product/Millipore
    Average 90 stars, based on 1 article reviews
    anti-integrin α5β1 primary antibody mab2514 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Millipore anti-integrin α5β1 primary antibody
    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against <t>α5β1</t> <t>integrin</t> and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.
    Anti Integrin α5β1 Primary Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-integrin α5β1 primary antibody/product/Millipore
    Average 90 stars, based on 1 article reviews
    anti-integrin α5β1 primary antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Millipore anti-integrin-α5β1 antibody
    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against <t>α5β1</t> <t>integrin</t> and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.
    Anti Integrin α5β1 Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-integrin-α5β1 antibody/product/Millipore
    Average 90 stars, based on 1 article reviews
    anti-integrin-α5β1 antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Merck & Co anti-mouse integrin α5β1 monoclonal antibody
    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against <t>α5β1</t> <t>integrin</t> and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.
    Anti Mouse Integrin α5β1 Monoclonal Antibody, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-mouse integrin α5β1 monoclonal antibody/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    anti-mouse integrin α5β1 monoclonal antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    Novus Biologicals α5β1
    FIGURE 5 Phenotyping characterization of human keratinocytes under xeno-free conditions. (a) Live phasecontrast microscopy images of keratinocytes after isolation from the epidermis of donor foreskin and at the confluency state. (b) The cumulative population doublings of keratinocytes cultured under xeno-free conditions is comparable to KGM-Gold medium. (c) Flow cytometry analysis confirmed the expression of integrins α2β1, <t>α5β1,</t> α6, α3, and β4, but not αvβ3. (d) Confocal microscopy exhibiting CK14, CK10, junctional ZO-1, and intracellular occludin staining. Scale bar = 100 μm. Representative of three independent donors
    α5β1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α5β1/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    α5β1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology α5β1
    FIGURE 5 Phenotyping characterization of human keratinocytes under xeno-free conditions. (a) Live phasecontrast microscopy images of keratinocytes after isolation from the epidermis of donor foreskin and at the confluency state. (b) The cumulative population doublings of keratinocytes cultured under xeno-free conditions is comparable to KGM-Gold medium. (c) Flow cytometry analysis confirmed the expression of integrins α2β1, <t>α5β1,</t> α6, α3, and β4, but not αvβ3. (d) Confocal microscopy exhibiting CK14, CK10, junctional ZO-1, and intracellular occludin staining. Scale bar = 100 μm. Representative of three independent donors
    α5β1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α5β1/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    α5β1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.

    Journal: Frontiers in Immunology

    Article Title: Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells

    doi: 10.3389/fimmu.2024.1470620

    Figure Lengend Snippet: Cell adhesion of different cancer cell lines in the presence or absence of NETs. Cells were seeded and allowed to adhere to NET-coated multi-well plates for 1, 2 or 4 h depending on the cell line (A–D) . Negative controls were plates coated with PBS or conditioned medium of dHL-60 and NET-coated plates pre-incubated with DNase I. Results are expressed as percentage of total cell number in each well. In parallel experiments, adherent cells were exposed to 0.5 µg/mL NETs for 48 h followed by counting of adherent and detached viable cells (E) . (A) Cell adhesion (mean ± SE) obtained in HCC827 (2 h), H1975 (2 h), H1993 (2 h) and A549 (1 h) lung cancer cell lines. (B) Cell adhesion (mean ± SE) obtained in MCF7 (2 h) and MDA MB231 (2 h) breast cancer cells, HT1080 fibrosarcoma (1 h) and U87-MG glioblastoma (4 h) cell lines. (C) Cell adhesion (mean ± SE) to NET-coated plates obtained in HCC827 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (D) Cell adhesion (mean ± SE) to NET-coated plates obtained in H1975 cells pre-incubated with blocking antibodies against α5β1 integrin and CCDC25 receptor. (E) Percentage of adherent and detached viable cells exposed or not to NETs in the medium for 48 h. Statistical significance: *p<0.05; **p< 0.01; ***p< 0.001; ns, not significant.

    Article Snippet: To test the role of α5β1 integrin and CCDC25 receptor in promoting cell adhesion to NETs, 3×10 5 cells were pre-incubated with 5μg/ml of blocking antibody recognizing α5β1 integrin (Millipore Cat# MAB2514, RRID: AB_94626) or CCDC25 (Thermo Fisher Scientific Cat# PA5-54735, RRID: AB_2639443) in 300μl of serum-free medium supplemented with 1% BSA for 1 h at 37°C and 5% CO 2 .

    Techniques: Incubation, Blocking Assay

    FIGURE 5 Phenotyping characterization of human keratinocytes under xeno-free conditions. (a) Live phasecontrast microscopy images of keratinocytes after isolation from the epidermis of donor foreskin and at the confluency state. (b) The cumulative population doublings of keratinocytes cultured under xeno-free conditions is comparable to KGM-Gold medium. (c) Flow cytometry analysis confirmed the expression of integrins α2β1, α5β1, α6, α3, and β4, but not αvβ3. (d) Confocal microscopy exhibiting CK14, CK10, junctional ZO-1, and intracellular occludin staining. Scale bar = 100 μm. Representative of three independent donors

    Journal: Bioengineering & translational medicine

    Article Title: 3D bioprinting of an implantable xeno-free vascularized human skin graft.

    doi: 10.1002/btm2.10324

    Figure Lengend Snippet: FIGURE 5 Phenotyping characterization of human keratinocytes under xeno-free conditions. (a) Live phasecontrast microscopy images of keratinocytes after isolation from the epidermis of donor foreskin and at the confluency state. (b) The cumulative population doublings of keratinocytes cultured under xeno-free conditions is comparable to KGM-Gold medium. (c) Flow cytometry analysis confirmed the expression of integrins α2β1, α5β1, α6, α3, and β4, but not αvβ3. (d) Confocal microscopy exhibiting CK14, CK10, junctional ZO-1, and intracellular occludin staining. Scale bar = 100 μm. Representative of three independent donors

    Article Snippet: ECs, FBs, PCs, and KCs cultured under xeno-free conditions were analyzed for surface and intracellular markers expression by flow cytometry and immunofluorescence microscopy using antibodies against: CD31 (WM59; Biolegend), CD45 (2D1; Biolegend), ZO-1 (sc-33725; Santa Cruz), VE-cadherin (sc-6458; Santa Cruz), vWF (ab201336; abcam) claudin-5 (34-1600; Invitrogen), PDGFR-α (16A1; Biolegend), PDGFR-β (18A2; Biolegend), CD90 (5E10; Biolegend), NG2 (9.2.27; Invitrogen), a-SMA (1A4; Invitrogen), FAP (AF3715; Novus Biologics), integrins α2β1 (ab24697; abcam), α5β1 (NBP2-52680; Novus Biologics), αvβ3 (sc-7312; Santa Cruz), α6 (MAB13501; R&D systems), α3 (MAB1345; R&D systems), β4 (NBP1-43369), CK14 (LL002; Novus Biologics), CK10 (EP1607IHCY, abcam), and occludin.

    Techniques: Microscopy, Isolation, Cell Culture, Flow Cytometry, Expressing, Confocal Microscopy, Staining